Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Profit-Taking Time for This Drug Stock


Use this opportunity to step out of this stock while it's in rally mode, and if you want exposure in the sector, put your money to use in one of its rivals.


Amgen (AMGN) is a company that has been in the Hare portfolio since 2002, and it has had a rocky tenure.

Instead of being a relatively steady firm, safety concerns arose for Amgen's main anemia drugs, which was unusual because they came after the drugs had spent several years on the market. We also saw government reimbursement pressures create a major headwind for the business.

Amgen is still a solid firm, but it is far from being the best of the best in the health-care sector. However, in recent weeks the stock has run up to near our $68 fair-value estimate, following a large share buyback and some excitement about the new CEO, even though these factors do not fundamentally improve the business. As such, it made the most sense to make room in the portfolio by bidding these shares "adieu."

One question I commonly receive is, "Why didn't you wait until it hit the 'consider sell' price before cutting the position?"

While I would most certainly sell at first chance a dollar bill trading for $1.35 (a 35% premium to fair value), I can also add value to the portfolio by selling dollar bills for $1 to recycle the capital back into other dollar bills that currently trade at, say, $0.70.

My strategy with the Tortoise and Hare is to minimize the dollar-weighted price/fair-value ratio of the portfolios while maximizing the dollar-weighted star ratings. The trades I made in January furthered both of these goals.

About Amgen and Its Valuation
Thanks to the promise of Prolia/Xgeva, we at my firm think Amgen is capable of maintaining its top line and supporting mid-single-digit bottom-line growth for the next five years in spite of the long list of challenges facing its established portfolio of drugs. Amgen's anemia drugs, Epogen and Aranesp, continue to see pressure from tougher labels and reimbursement.

Patents on all five of Amgen's blockbusters begin to expire by 2015, making the firm a prime target for companies developing biosimilars, including Merck (MRK) and Teva (TEVA). While Amgen is flush with cash to pour into R&D and acquisitions, our enthusiasm is tempered by a late-stage pipeline that's heavily reliant on a handful of high-risk cancer drug candidates.

For example, motesanib recently failed after being held up in Phase III trials for years due to safety issues. New Phase III candidate AMG 386 could face stiff competition from Roche's (RHHBY.PK) Avastin in ovarian cancer.

We raised our fair-value estimate for Amgen to $68 per share from $65, based largely on the expected reduction in the number of shares following the $5 billion tender offer in December 2011.

We expect combined sales of Prolia/Xgeva to peak at $5 billion, with more than $3 billion from Xgeva alone. Pressure on sales of erythropoiesis-stimulating agents (or ESAs) has continued into 2011, and ESA sales growth should remain in negative territory for the foreseeable future.

We anticipate generic competition to Epogen in the US by 2013, and Aranesp as early as 2015. Sales growth from Prolia/Xgeva-and to a lesser extent Nplate-should largely neutralize this pressure on top-line sales, and we model flat sales during the next five years.

We assume that Amgen's 39% oper-ating margin (excluding amortization expense) should decline by about 300 basis points during the next 10 years, as a smaller percentage of sales will stem from older, more profitable biologics.

We don't believe that improved efficiency, cost-saving measures, and the end of Enbrel profit sharing with Pfizer (PFE) will be able to counter pressure from biosimilars. During the next five years, our earnings per share growth rate averages 6%, largely due to continued share repurchases.

We model a 70% probability of approval for Prolia to delay the development of bone metas-tases in 2012, an indication that could be worth roughly $1.9 billion of our $5 billion assumed peak sales potential of Prolia/Xgeva.

Editor's Note: This article was written by Paul Larson of Morningstar StockInvestor.

Below, find some more great investing and trading content from MoneyShow:

4 Techs to Watch for Buy Points
By Kate Stalter

Don't Take the Bear Bait
By Igor Greenwald

Look to the Silver Explorers
By Tyler Laundon

7 Yellow Flags to Watch For
By Bob Carlson

Twitter: @TopProsTopPicks

No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos